预约演示
Nuvectis receives orphan drug designation for cholangiocarcinoma therapy
2023-08-18
孤儿药快速通道临床1期
Cholangiocarcinoma accounts for approximately 3% of all gastrointestinal malignancies. Credit: Explode / Shutterstock.com.
Cholangiocarcinomas received orphan drug designation frogastrointestinal malignanciesstration (FDA) for NXP800 to treat cholangiocarcinoma.
Nuvectis Pharma molecule taken orally, is currently being assesseFood and Drug Administration (FDA)NXP800cholangiocarcinoma
NXP800ended Reports
ReportsLOA and PTSR Model - Camrelizumab in Malignant Pleural Mesothelioma GlobalData
ReportsLOA and PTSR Model - Anetumab Corixetan in Malignant Mesothelioma GlobalData
View allCompanies IntelligenCamrelizumabharmMalignant Pleural Mesothelioma
The study is designed to explore the drug candidate’s clinical activity as a potential treatment for platinum-resistant, ARID1a-mutated ovarian carcinoma.
Nuvectis has already receiveAnetumabrCorixetannatiMalignant Mesotheliomalopment programme.
It is also developing another drug candidate, NXP900, a new small molecule inhibitor targeting the SRC/YES1 kinases.
The FDA has cleared the IND for NXP900 and a Phase Ia dose escalation trial is yet to commence.ARID1a
“This orphan drug designation is an important NXP900one in our journey toward our mission of developing NXP800 for the treatment of serious conditions of unmet medical need in oncology.”
Nuvectisannual incidence of nearly 8,000 to 10,NXP800 the US, it accounts for around 3% of all gastrointestinal malignancies.cancerARID1a-mutated ovarian, endometrial and gastric carcinomasARID1acholangiocarcinoma
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。